In our last blog we talked about the importance of site level insights in making solid decisions about which investigators can successfully support your trial. In this blog we give further insights about how ClinSite can support decision making on investigator site selection in NASH, a fiercely competitive space for investigator site patient enrollment.
When we launched ClinSite at DIA in San Diego in June, there was a lot of discussion about NASH (nonalcoholic steatohepatitis) and a lot of interest in how Phesi’s proprietary analytics platform could support better design, planning and execution of NASH trials. We thought we would complete some high-level analysis to share with the global life sciences community that might be of interest.
Global competition for enrolling sites is significant and has grown exponentially over the last 2-3 years. Data is dynamically refreshed in ClinSite:
Using ClinSite clients can look at the activity by country helping inform country allocation discussions and ‘what if’ scenario planning internally and with partner CROs:
One key challenge will be finalizing the number and names of investigators required. An experienced investigator with track record of enrollment performance in the indication under study (including biomarkers, comparator etc.) and preferably with limited competition at site from other trials plus insight into capacity to recruit is what sponsors are looking for. Below are sample representative profile and capacity/ activity data which can be extracted in key strokes using ClinSite:
Accessing such data, along with name and contact details, that ClinSite also provides, helps clients make better decisions in a highly competitive trial.
In our next post we will show example NASH analysis on the impact of trial design on enrollment cycle time, predicting the number of investigator sites required and global KOL identification.